Glenmark Pharmaceuticals Limited (BOM:532296)

Glenmark Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	13,619	10,471	-15,017	2,972	9,417
Depreciation & Amortization	5,735	3,594	4,792	3,810	1,613
Other Amortization	-	1,266	1,517	2,303	3,254
Loss (Gain) From Sale of Assets	170.18	25.42	-8.26	-57.25	64.64
Loss (Gain) From Sale of Investments	-0.25	0.27	-7,450	-0.26	-149.81
Stock-Based Compensation	268.05	-91.67	49.62	67.74	79.16
Provision & Write-off of Bad Debts	201.25	30.97	176.5	118.72	298.74
Other Operating Activities	18,929	1,715	15,928	1,499	2,122
Change in Accounts Receivable	-17,505	-14,203	9,695	-8,487	-5,493
Change in Inventory	-7,523	-4,508	-5,139	-3,752	-2,034
Change in Accounts Payable	27,046	-8,138	-7,344	1,662	847.57
Change in Other Net Operating Assets	-6,489	1,562	-5,182	-167.73	1,067
Operating Cash Flow	34,450	-8,276	-2,654	6,254	11,087
Operating Cash Flow Growth	-	-	-	-43.59%	-1.99%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-13,577	-7,496	-8,984	-6,078	-7,901
Sale of Property, Plant & Equipment	23.3	24.2	20.8	572.29	15.8
Divestitures	-	7,450	54,496	-	-
Investment in Securities	305.69	-93.03	70.51	-10.08	-100.18
Other Investing Activities	415.75	135.16	5.31	230.51	4,653
Investing Cash Flow	-12,832	20.94	45,609	-5,285	-3,333

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	-	8,339	4,811	-	-
Long-Term Debt Issued	-	5,072	-	11,632	21,301
Total Debt Issued	-	13,412	4,811	11,632	21,301
Short-Term Debt Repaid	-17,157	-	-	-200	-1,417
Long-Term Debt Repaid	-6,416	-2,629	-37,539	-6,198	-31,201
Total Debt Repaid	-23,573	-2,629	-37,539	-6,398	-32,618
Net Debt Issued (Repaid)	-23,573	10,783	-32,728	5,234	-11,317
Issuance of Common Stock	7.59	-	12	-	-
Common Dividends Paid	-1,410	-704.42	-704.52	-703.86	-926.95
Other Financing Activities	-2,111	-2,208	-5,641	-5,305	7,040
Financing Cash Flow	-27,087	7,870	-39,061	-774.56	-5,205

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	459.59	558.93	176.79	123.87	175.5
Miscellaneous Cash Flow Adjustments	-0.04	-	-1,918	6.68	-
Net Cash Flow	-5,010	174.37	2,152	325	2,724

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	20,873	-15,772	-11,638	176.29	3,185
Free Cash Flow Growth	-	-	-	-94.47%	-10.64%
Free Cash Flow Margin	12.29%	-11.80%	-9.20%	0.15%	2.59%
Free Cash Flow Per Share	73.94	-55.89	-41.24	0.63	11.29
Levered Free Cash Flow	11,774	-16,058	43,246	-11,604	1,853
Unlevered Free Cash Flow	13,078	-14,764	46,471	-9,423	3,716

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	2,111	1,908	5,168	3,115	2,505
Cash Income Tax Paid	7,830	6,801	10,475	6,405	5,584
Change in Working Capital	-4,471	-25,287	-7,970	-10,745	-5,613

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 2, 2026

Data Sources Report a data error